Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Current Adoptive Immunotherapy in Non-Small Cell Lung Cancer and Potential Influence of Therapy Outcome
Ya-Wen Zheng, Run-Mei Li, Xinwei Zhang, et al.
Cancer Investigation (2013) Vol. 31, Iss. 3, pp. 197-205
Closed Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer
Jiabei He, Ying Hu, Mingming Hu, et al.
Scientific Reports (2015) Vol. 5, Iss. 1
Open Access | Times Cited: 376
Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities
Barbara Merelli, Daniela Massi, Laura Cattaneo, et al.
Critical Reviews in Oncology/Hematology (2013) Vol. 89, Iss. 1, pp. 140-165
Closed Access | Times Cited: 163
Intratumor IL-17-Positive Mast Cells Are the Major Source of the IL-17 That Is Predictive of Survival in Gastric Cancer Patients
Xiaosun Liu, Hailong Jin, Geer Zhang, et al.
PLoS ONE (2014) Vol. 9, Iss. 9, pp. e106834-e106834
Open Access | Times Cited: 58
Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine induced killer immunotherapy on recurrence and survival rate of non-small cell lung cancer patients
Min Zhao, Hongbing Li, Lei Li, et al.
Experimental and Therapeutic Medicine (2014) Vol. 7, Iss. 5, pp. 1403-1407
Open Access | Times Cited: 42
Effectiveness and Safety of Chemotherapy Combined with Dendritic Cells Co-Cultured with Cytokine-Induced Killer Cells in the Treatment of Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
Rui-xian Han, Xu Liu, Pan Pan, et al.
PLoS ONE (2014) Vol. 9, Iss. 9, pp. e108958-e108958
Open Access | Times Cited: 39
Clinical significance of serum T helper 1/T helper 2 cytokine shift in patients with non-small cell lung cancer
Jun Li, Zhenhua Wang, Kai Mao, et al.
Oncology Letters (2014) Vol. 8, Iss. 4, pp. 1682-1686
Open Access | Times Cited: 36
Effectiveness of immune therapy combined with chemotherapy on the immune function and recurrence rate of cervical cancer
Bin Chen, Lifen Liu, Haiyan Xu, et al.
Experimental and Therapeutic Medicine (2015) Vol. 9, Iss. 3, pp. 1063-1067
Open Access | Times Cited: 36
Recent advances in postoperative pulmonary rehabilitation of patients with non‑small cell lung cancer (Review)
Xue-e Su, Wan-Ping Hong, He-fan He, et al.
International Journal of Oncology (2022) Vol. 61, Iss. 6
Open Access | Times Cited: 17
Metformin inhibits lung cancer cells proliferation through repressing microRNA-222
Yuqi Wang, Wei-Min Dai, Xiangyang Chu, et al.
Biotechnology Letters (2013) Vol. 35, Iss. 12, pp. 2013-2019
Closed Access | Times Cited: 34
Interferon induced transmembrane protein 3 regulates the growth and invasion of human lung adenocarcinoma
Dong Zhang, Huimin Wang, Huijie He, et al.
Thoracic Cancer (2017) Vol. 8, Iss. 4, pp. 337-343
Open Access | Times Cited: 32
Comprehensive Assessment of Serum hsa_circ_0070354 as a Novel Diagnostic and Predictive Biomarker in Non-small Cell Lung Cancer
Yuejiao Huang, Shiyi Qin, Xinliang Gu, et al.
Frontiers in Genetics (2022) Vol. 12
Open Access | Times Cited: 14
Advances in the Lung Cancer Immunotherapy Approaches
Hafiza Padinharayil, Reema Rose Alappat, Liji Maria Joy, et al.
Vaccines (2022) Vol. 10, Iss. 11, pp. 1963-1963
Open Access | Times Cited: 13
Antiangiogenic therapy improves the antitumor effect of adoptive cell immunotherapy by normalizing tumor vasculature
Shujing Shi, Longbang Chen, Guichun Huang
Medical Oncology (2013) Vol. 30, Iss. 4
Closed Access | Times Cited: 23
Programmed cell death‐ligand 1 (PD‐L1) expression and fibroblast growth factor receptor 1 (FGFR1) amplification in stage III/IV lung squamous cell carcinoma (SQC)
Qinxiang Guo, Yu Sun, Sifan Yu, et al.
Thoracic Cancer (2016) Vol. 8, Iss. 2, pp. 73-79
Open Access | Times Cited: 18
5-Fluorouracil and Interleukin-2 Immunochemotherapy Enhances Immunogenicity of Non-Small Cell Lung Cancer A549 Cells through Upregulation of NKG2D Ligands
Lei Zhao, Wenjia Wang, Jinnan Zhang, et al.
Asian Pacific Journal of Cancer Prevention (2014) Vol. 15, Iss. 9, pp. 4039-4044
Open Access | Times Cited: 18
TACE combined with dendritic cells and cytokine-induced killer cells in the treatment of hepatocellular carcinoma: A meta-analysis
Guangzhi He, Chenhong Zheng, Hui-ping Huo, et al.
International Immunopharmacology (2016) Vol. 40, pp. 436-442
Closed Access | Times Cited: 17
Efficacy of DC-CIK Immunotherapy Combined with Chemotherapy on Locally Advanced Gastric Cancer
Guiyuan Liu, Dehu Chen, Xiao-Jun Zhao, et al.
Journal of Oncology (2022) Vol. 2022, pp. 1-6
Open Access | Times Cited: 9
Immune checkpoints and immunotherapy in non‑small cell lung cancer: Novel study progression, challenges and solutions (Review)
Lin-Rui Ma, Jiaxin Li, Ling Tang, et al.
Oncology Letters (2021) Vol. 22, Iss. 5
Open Access | Times Cited: 11
Plasmodium immunotherapy combined with gemcitabine has a synergistic inhibitory effect on tumor growth and metastasis in murine Lewis lung cancer models
Xiao Chen, Zhu Tao, Yun Liang, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 4
Preclinical data on the combination of cisplatin and anti-CD70 therapy in non-small cell lung cancer as an excellent match in the era of combination therapy
Julie Jacobs, Vanessa Deschoolmeester, Christian Rolfo, et al.
Oncotarget (2017) Vol. 8, Iss. 43, pp. 74058-74067
Open Access | Times Cited: 12
CHAF1A, the largest subunit of the chromatin assembly factor?1 complex, regulates the growth of H1299 human non‑small cell lung cancer cells by inducing G0/G1 cell cycle arrest
Tanzhen Liu, Jingjing Wei, Chao Jiang, et al.
Experimental and Therapeutic Medicine (2017)
Open Access | Times Cited: 12
Impact of Cellular Immune Function on Prognosis of Lung Cancer Patients after Cytokine-induced Killer Cell Therapy
Congguo Jin, Jia Li, Yeying Wang, et al.
Asian Pacific Journal of Cancer Prevention (2014) Vol. 15, Iss. 15, pp. 6009-6014
Open Access | Times Cited: 11
Meta-analysis of chemotherapy and dendritic cells with cytokine-induced killer cells in the treatment of non-small-cell lung cancer.
Chenhong Zheng, Ganjun Yu, Hui Wang, et al.
PubMed (2015) Vol. 8, Iss. 8, pp. 14527-37
Closed Access | Times Cited: 10
Adoptive immunotherapy combined chemoradiotherapy for non-small-cell lung cancer
Haili Qian, Haijuan Wang, Xiuwen Guan, et al.
Anti-Cancer Drugs (2016) Vol. 27, Iss. 5, pp. 433-438
Closed Access | Times Cited: 5
Inhibitor of ghrelin receptor reverses gefitinib resistance in lung cancer
Xiaoyou Li, Xia Zhao, Chenchen Li, et al.
Human Cell (2019) Vol. 32, Iss. 3, pp. 360-366
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top